Literature DB >> 17339583

Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.

M S Forman1, E J Mufson, S Leurgans, D Pratico, S Joyce, S Leight, V M-Y Lee, J Q Trojanowski.   

Abstract

OBJECTIVE: Mild cognitive impairment, hypothesized to be prodromal Alzheimer disease (AD), shows abundant senile plaques and neurofibrillary tangles, but its biochemical correlates remain undefined.
METHODS: Biochemical profiles of Abeta, tau, alpha-synuclein, and oxidative pathologies were characterized in middle frontal gyrus, inferior parietal cortex, and entorhinal cortex in postmortem frozen brains from subjects diagnosed antemortem with no cognitive impairment, mild cognitive impairment, or AD.
RESULTS: Insoluble Abeta and tau, as well as tissue isoprostanes, from each brain region analyzed did not correlate with the clinical diagnosis proximate to death, but insoluble Abeta and 8,12-iso-iPF(2alpha)-VI levels from gray matter of all brain regions correlated strongly with the burden of AD pathology, whereas insoluble tau did not.
CONCLUSIONS: The biochemical alterations in cortical tau, Abeta, and isoprostane do not reflect the onset of clinical dementia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339583     DOI: 10.1212/01.wnl.0000256373.39415.b1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

2.  Plasma F2-isoprostane level and cognitive function over eight years in non-demented older adults: Findings from the Health ABC Study.

Authors:  A J Fiocco; A M Kanaya; K M Lindquist; T B Harris; S Satterfield; E M Simonsick; L Kuller; C Rosano; K Yaffe
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-09-25       Impact factor: 4.006

Review 3.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

4.  Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease.

Authors:  Cyntia Tremblay; Isabelle St-Amour; Julie Schneider; David A Bennett; Frédéric Calon
Journal:  J Neuropathol Exp Neurol       Date:  2011-09       Impact factor: 3.685

Review 5.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Authors:  Victor L Villemagne; Vincent Doré; Samantha C Burnham; Colin L Masters; Christopher C Rowe
Journal:  Nat Rev Neurol       Date:  2018-02-16       Impact factor: 42.937

6.  Is AD a homogeneous nosologic entity? Yes.

Authors:  P Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-07-05       Impact factor: 3.575

7.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

Review 8.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Alzheimer's disease and neuronal network activity.

Authors:  Marc Gleichmann; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2009-11-03       Impact factor: 3.843

Review 10.  Impact of amyloid imaging on drug development in Alzheimer's disease.

Authors:  Chester A Mathis; Brian J Lopresti; William E Klunk
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.